Special Surgery 11. Malignant Diseases of the Gallbladder and the Biliary Tract: Symptomatics, Diagnostics and Treatments

I. Gallbladder Carcinoma

Definition and Epidemiology

• Malignant tumor from gallbladder mucosal lining
• Histology: mostly adenocarcinoma
• Rare but highly aggressive
• More common in women
• Often diagnosed incidentally during/after cholecystectomy for presumed benign gallstone disease

Risk Factors

• Cholelithiasis with chronic inflammation
• Large gallstones
• Chronic cholecystitis
• Porcelain gallbladder: calcified gallbladder wall
• Gallbladder polyp > 1 cm, sessile, growing or symptomatic
• Anomalous pancreaticobiliary junction
• Female sex, older age

Clinical Features

• Early stage: often asymptomatic
• Can mimic gallstone disease / chronic cholecystitis
• RUQ pain or biliary colic-like pain
• Weight loss, anorexia, nausea, vomiting
• Jaundice: late, from bile duct invasion/compression or hilar involvement
• Advanced disease: palpable mass, hepatomegaly, ascites

Diagnosis

• Labs: bilirubin, ALP/GGT, AST/GOT, ALT/GPT can increase if obstruction/liver invasion exists
• Tumor markers: CA 19-9 and CEA supportive/follow-up markers, not diagnostic
• Transabdominal US: mass, irregular wall thickening, loss of normal layers, polypoid lesion, liver invasion
• CT chest/abdomen/pelvis: local invasion, liver involvement, lymph nodes, vascular invasion, metastasis
• MRI/MRCP: bile duct involvement and vascular/liver invasion
• Histology: often after cholecystectomy; biopsy if unresectable/metastatic disease is suspected before systemic therapy

Treatment

1. Incidental Cancer after Cholecystectomy

• T1a: simple cholecystectomy is usually sufficient if margins are negative
• T1b or higher: re-resection / extended radical cholecystectomy if fit and no metastasis

• Liver wedge resection or segments IVb/V resection
• Portal/hepatoduodenal ligament lymphadenectomy
• Extrahepatic bile duct resection only if involved or needed for negative margin

2. Known Resectable Tumor

• Radical cholecystectomy:

• Cholecystectomy
• En bloc liver resection of gallbladder bed, usually wedge or segments IVb/V
• Regional lymphadenectomy
• Adjacent organ resection only if directly invaded and R0 is possible

3. Unresectable / Metastatic Tumor

• Palliative biliary stent or percutaneous drainage for obstructive jaundice/cholangitis/pruritus
• Systemic therapy: gemcitabine + cisplatin backbone; immunotherapy/targeted therapy in selected protocols
• Supportive care: pain control, nutrition, cholangitis treatment, palliative care

II. Cholangiocarcinoma

Definition and Epidemiology

• Malignant tumor from epithelial cells of biliary ducts
• Histology: adenocarcinoma
• Peak incidence: 60-70 years
• Male predominance in many series

Classification

1. Intrahepatic: small-medium bile ducts within liver
2. Extrahepatic: large bile ducts, more common

• Perihilar / Klatskin tumor: at hepatic duct bifurcation / hilum
• Distal extrahepatic: common bile duct near pancreas/ampulla

Bismuth-Corlette Classification: Perihilar Tumors

• Type I: below hepatic duct bifurcation
• Type II: reaches bifurcation/confluence
• Type IIIa: extends into right hepatic duct
• Type IIIb: extends into left hepatic duct
• Type IV: involves both right and left hepatic ducts / multifocal hilar involvement

Risk Factors

• Primary sclerosing cholangitis (PSC)
• Choledocholithiasis / hepatolithiasis and chronic biliary inflammation
• Choledochal cysts
• Liver flukes: Clonorchis sinensis, Opisthorchis
• Liver cirrhosis
• Chronic viral hepatitis, especially for intrahepatic type

Clinical Features

• Extrahepatic tumors: progressive painless obstructive jaundice is typical
• Cholestasis → jaundice, dark urine, acholic/pale stools, pruritus
• Weight loss, anorexia, fatigue
• RUQ discomfort; severe pain is less typical early
• Fever/chills if cholangitis develops
• Intrahepatic type: liver mass with RUQ pain/weight loss, often less jaundice
• Courvoisier sign: palpable, painless, enlarged gallbladder + obstructive jaundice → malignant distal biliary obstruction

Diagnosis

• Labs: cholestatic pattern with increased direct bilirubin, ALP, GGT; AST/GOT and ALT/GPT can increase
• Tumor markers: CA 19-9 and CEA supportive only; CA 19-9 can be falsely high in cholangitis/obstructive jaundice
• Transabdominal US: first-line; localizes obstruction by showing dilated bile ducts
• MRCP: best non-invasive map of biliary tree; key for definitive mapping and surgical planning
• CT/MRI: local extension, vascular invasion, liver involvement, lymph nodes, metastasis/resectability
• ERCP: distal obstruction; brush cytology/biopsy + biliary stent
• PTC/PTBD: high hilar obstruction or failed ERCP; drainage and sampling
• Tissue diagnosis: difficult and sometimes falsely negative; especially needed before chemotherapy or if unresectable/metastatic

Treatment

• Only curative treatment: R0 surgical resection if resectable and patient fit
• Major biliary cancer surgery should be done in hepatopancreatobiliary centers
• Drain cholangitis urgently; preoperative biliary drainage is selective, not automatic for all jaundiced patients

1. Intrahepatic Cholangiocarcinoma

• Liver resection with negative margins
• Regional lymphadenectomy often added for staging/clearance

2. Perihilar Cholangiocarcinoma / Klatskin Tumor

• Operation usually requires:

• Extrahepatic bile duct resection
• Major hepatectomy depending on side/extent
• Caudate lobe resection often needed
• Regional lymphadenectomy
• Roux-en-Y hepaticojejunostomy reconstruction

3. Distal Extrahepatic Cholangiocarcinoma

• Pancreaticoduodenectomy / Whipple procedure + regional lymphadenectomy
• Whipple includes pancreatic head, duodenum, gallbladder, distal CBD and reconstruction

4. Unresectable / Metastatic Disease

• Palliative biliary stent/drainage via ERCP or PTC for decompression
• Systemic chemotherapy: gemcitabine + cisplatin backbone
• Selected centers/protocols: immunotherapy, targeted therapy after molecular testing, radiotherapy or photodynamic therapy
• Liver transplantation: selected perihilar cases only under strict protocols after neoadjuvant therapy

III. Shared Staging / Prognosis

Resectability Assessment

• Assess distant metastasis, peritoneal disease, lymph nodes and vascular invasion
• For hilar tumors: assess right/left duct involvement and portal vein/hepatic artery relation
• For major liver resection: assess future liver remnant volume/function
• Separate tumor resectability from patient operability/fitness
• Onco-team / hepatopancreatobiliary center decision is essential

Prognosis

• Generally poor because symptoms occur late
• Best prognosis: incidental early T1a gallbladder cancer fully removed by cholecystectomy
• Worse prognosis: positive margins, lymph node metastasis, vascular/perineural invasion, peritoneal/distant metastasis, poor fitness, cholangitis/malnutrition

IV. Exam Summary

• Gallbladder carcinoma: often incidental; risk factors are gallstones, chronic cholecystitis, porcelain gallbladder and large polyps
• Gallbladder carcinoma treatment: T1a simple cholecystectomy; T1b or higher extended cholecystectomy if fit and non-metastatic
• Cholangiocarcinoma: biliary duct adenocarcinoma causing painless obstructive jaundice
• MRCP maps cholangiocarcinoma and level of obstruction
• Curative cholangiocarcinoma surgery depends on location: intrahepatic = liver resection, perihilar = bile duct resection + hepatectomy/caudate often, distal = Whipple
• Unresectable disease: biliary drainage/stent + systemic therapy/palliation